In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Reinfection outcomes (Research Square)
CDC recommends vaccine for young children (CDC)
Neurodevelopment outcomes in infants post-infection (JAMA)
Efficacy of monoclonal antibodies/antivirals in hamsters (Nature)
PAXLOVID patient eligibility screening checklist (FDA)
Remdesivir fact sheet for providers (Veklury)
Bebtelovimab fact sheet for providers (FDA)
PAXLOVID drug interaction checker
Rebound phenomenon after PAXLOVID in high-risk persons (IDSA)
Hospitalization for infection after PAXLOVID treatment (CDC)
Risk of post acute infection with different variants (the Lancet)
Contribute to FIMRC fundraiser at PWB
Dr. Griffin’s treatment guide (pdf)
Letters read on TWiV 912
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 912: COVID-19 clinical update #120 with Dr. Daniel Griffin